Nuclear Medicine and Molecular Imaging

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Clinical Usefulness of Dopamine Transporter Imaging

도파민운반체 영상의 임상적 유용성

  • Kim, Jong-Min (Departments of Neurology, Seoul National University College of Medicine, MRC and BK-21, Clinical Research Institute, Seoul National University Hospital and Bundang Hospital) ;
  • Kim, Yu-Kyeong (Departments of Nuclear Medicine, Seoul National University College of Medicine, MRC and BK-21, Clinical Research Institute, Seoul National University Hospital and Bundang Hospital) ;
  • Kim, Sang-Eun (Departments of Nuclear Medicine, Seoul National University College of Medicine, MRC and BK-21, Clinical Research Institute, Seoul National University Hospital and Bundang Hospital) ;
  • Jeon, Beom-S. (Departments of Neurology, Seoul National University College of Medicine, MRC and BK-21, Clinical Research Institute, Seoul National University Hospital and Bundang Hospital)
  • 김종민 (서울대학교 의과대학 신경과학교실) ;
  • 김유경 (서울대학교 의과대학 핵의학교실) ;
  • 김상은 (서울대학교 의과대학 핵의학교실) ;
  • 전범석 (서울대학교 의과대학 신경과학교실)
  • Published : 2007.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Imaging of the dopamine transporter (DAT) provides a marker for the integrity of presynaptic nigrostriatal dopaminergic system. DAT density is reduced in Parkinson disease, multiple system atrophy, and progressive supranuclear palsy. In patients with suspicious parkinsonism, normal DAT imaging suggests an alternative diagnosis such as essential tremor, vascular parkinsonism, or drug-induced parkinsonism. DAT imaging is a useful tool to aid clinician's differential diagnosis in parkinsonism.

Keywords

References

  1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson󰡑s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4 https://doi.org/10.1136/jnnp.55.3.181
  2. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999;28: 99-102 https://doi.org/10.1093/ageing/28.2.99
  3. Geraghty JJ, Jankovic J, Zetusky WJ. Association between essential tremor and Parkinson's disease. Ann Neurol 1985;17:329-33 https://doi.org/10.1002/ana.410170404
  4. Winikates J Jankovic J. Clinical correlates of vascular parkinsonism. Arch Neurol 1999;56:98-102 https://doi.org/10.1001/archneur.56.1.98
  5. Gerschlager W, Bencsits G, Pirker W, Bloem BR, Asenbaum S, Prayer D, et al. [$^{123}I$]-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov Disord 2002;17:518-23 https://doi.org/10.1002/mds.10092
  6. Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 1999;122:1449-68 https://doi.org/10.1093/brain/122.8.1449
  7. Rinne JO, Laine M, Kaasinen V, Norvasuo-Heila MK, Nagren K, Helenius H. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology 2002;58:1489-93 https://doi.org/10.1212/WNL.58.10.1489
  8. Brucke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wober C, et al. Measurement of the dopaminergic degeneration in Parkinson's disease with [$^{123}I$] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 1997; 50:9-24
  9. Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP. [$^{123}I$]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord 2001;16:1023-32 https://doi.org/10.1002/mds.1256
  10. Pirker W, Asenbaum S, Bencsits G, Prayer D, Gerschlager W, Deecke L, et al. [$^{123}I$]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 2000;15:1158-67 https://doi.org/10.1002/1531-8257(200011)15:6<1158::AID-MDS1015>3.0.CO;2-0
  11. Kim YJ, Ichise M, Ballinger JR, Vines D, Erami SS, Tatschida T, et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 2002;17:303-12 https://doi.org/10.1002/mds.10042
  12. Stephen PJ, Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984;2:1082-3
  13. Marti Masso JF, Carrera N, Urtasun M. Drug-induced parkinsonism: a growing list. Mov Disord 1993;8:125 https://doi.org/10.1002/mds.870080127
  14. Rajput AH, Rozdilsky B, Hornykiewicz O, Shannak K, Lee T, Seeman P. Reversible druginduced parkinsonism. Clinicopathologic study of two cases. Arch Neurol 1982;39:644-6 https://doi.org/10.1001/archneur.1982.00510220042009
  15. Chabolla DR, Maraganore DM, Ahlskog JE, O'Brien PC, Rocca WA. Drug-induced parkinsonism as a risk factor for Parkinson's disease: a historical cohort study in Olmsted County, Minnesota. Mayo Clin Proc 1998;73:724-7 https://doi.org/10.4065/73.8.724
  16. Tolosa E, Coelho M, Gallardo M. DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord 2003;Suppl 7:S28-33
  17. Jankovic J. Progression of Parkinson disease: are we making progress in charting the course? Arch Neurol 2005;62:351-2 https://doi.org/10.1001/archneur.62.3.351
  18. Jeon BS, Jeong JM, Park SS, Kim JM, Chang YS, Song HC, et al. Dopamine transporter density measured by [123I]beta-CIT singlephoton emission computed tomography is normal in doparesponsive dystonia. Ann Neurol 1998;43:792-800 https://doi.org/10.1002/ana.410430614
  19. Jeon B, Kim JM, Jeong JM, Kim KM, Chang YS, Lee DS, et al. Dopamine transporter imaging with [$^{123}I$]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease. J Neurol Neurosurg Psychiatry 1998;65:60-4 https://doi.org/10.1136/jnnp.65.1.60
  20. Kim Y, Kim JM, Kim JW, Yoo CI, Lee CR, Lee JH, et al. Dopamine transporter density is decreased in parkinsonian patients with a history of manganese exposure: what does it mean? Mov Disord 2002;17:568-75 https://doi.org/10.1002/mds.10089
  21. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-61 https://doi.org/10.1001/jama.287.13.1653
  22. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003;54: 93-101 https://doi.org/10.1002/ana.10609